Michael J Fusco

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Vascular Endothelial Growth Factor

Metastatic Colorectal Cancer

Top Venues

Cancer discovery

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer control : journal of the Moffitt Cancer Center

This page only lists publications with an associated author ORCID identifier.

Publications

Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Michael J Fusco, Sandra J Casak, Sirisha L Mushti, Joyce Cheng, Brian J Christmas, Matthew D Thompson, Wentao Fu, Hezhen Wang, Miyoung Yoon, Yuching Yang, Jason N Moore, Youwei Bi, Yang Nan, Craig E Long, Doris Auth, Nam Atiqur Rahman, Shenghui Tang, Richard Pazdur, Lola A Fashoyin-Aje, Paul G Kluetz, Steven J Lemery
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Elizabeth S Duke, Michael J Fusco, Patrick DeMoss, Asma Dilawari, Gulsum E Pamuk, Jessica Boehmer, Bronwyn D Mixter, Kirsten B Goldberg, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development. Cancer discovery 12 (12) (2022)
Michael J Fusco, Yolanda Piña, Robert J Macaulay, Solmaz Sahebjam, Peter A Forsyth, Edwin Peguero, Christine M Walko
Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas. Cancer control : journal of the Moffitt Cancer Center 28 (2022)
Michael J Fusco, Todd C Knepper, Juliana Balliu, Alex Del Cueto, Jose M Laborde, Sharjeel M Hooda, Andrew S Brohl, Marilyn M Bui, J Kevin Hicks
Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary. The oncologist 27 (1) (2022)